This Group is Advisory Board Member Group of UAE Health Network.

The Group share the vision to promote networking site in order to allow healthcare professional to network, share and educate. Group Participates Regularly about developmen

46 Members
Join Us!

Advisory Board Member's Goal

- To create a professional healthcare social networking site in the interest of UAE Health industry
- To promote site to Healthcare Professional for better utilization of networking resources
- To add content on the site relevant to the site
- To monitor UAE Health Network activities regularly in the interest of the UAE HealthCare Network
- To support, protect and flourish UAE Health Network
- To participate in networking site development program

You need to be a member of Global Healthcare Network by DrPrem.com to add comments!

Comments

  • Thank you for adding me to the group - See us in Abu Dhabi -
    Yours
    FRIED
  • Admin
    Dear Advisory Board Members,

    We invite your suggestions and comments for further development of the networking site. Please write your views in comments section of this group.

    regards,

    Dr Prem Jagyasi
  • Admin
    Dear Group Members,

    Can we start sharing views about how to improve this network and how we can promote this network to concern industry stake holder.

    also, I request all to not use this group for any other news or promotion.

    regards,

    Dr Prem
  • FDA Gives Abbott Molecular Warning Letter
    Posted on November 24, 2009 @ 09:56 am


    Abbott Molecular has received a warning letter from the U.S. Food and Drug Administration, citing poor manufacturing standards at its Des Plaines, Ill., plant.

    Agency inspectors visited the facility in June. The results:


    • Failure to maintain and implement complete procedures for acceptance or rejection of finished device production runs, lots, or batches as required by 21 CFR § 820,80(d).

    • Failure to adequately control products that do not conform to specifications as required by 21 CFR § 820.90(a).

    • Failure to establish and follow procedures for the identification, documentation, and validation or verification of design changes prior to the implementation of the changes as required by 21 CFR § 820.30(i).

    • Failure to have completely defined procedures for implementing corrective and preventive actions as required by 21 CFR § 820.100(a).

    • Failure to identify acceptance criteria for design outputs as required by 21 CFR § 820.30(d).

    • Failure to completely define the corrective and preventive action procedures addressing the investigation of the cause of nonconformities relating to product, processes, and the quality system as required by 21 CFR § 820.100(a)(2).


    Visit www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm189807.htm to see the complete warning letter.
  • how do we promote the site to get more clinicians join and discuss their top issues
This reply was deleted.